APA (7th ed.) Citation

Garrigós, L., Ruiz-Borrego, M., Pérez-García, J., Guerrero-Zotano, A., Cortés-Salgado, A., Kuemmel, S., . . . Iacobucci, S. (2026). A chemotherapy-free, pathological response-adapted strategy using trastuzumab–pertuzumab and T-DM1 in HER2-positive early breast cancer: The PHERGain-2 study. Annals of Oncology, 37(6), 837. https://doi.org/10.1016/j.annonc.2026.01.013

Chicago Style (17th ed.) Citation

Garrigós, L., et al. "A Chemotherapy-free, Pathological Response-adapted Strategy Using Trastuzumab–pertuzumab and T-DM1 in HER2-positive Early Breast Cancer: The PHERGain-2 Study." Annals of Oncology 37, no. 6 (2026): 837. https://doi.org/10.1016/j.annonc.2026.01.013.

MLA (9th ed.) Citation

Garrigós, L., et al. "A Chemotherapy-free, Pathological Response-adapted Strategy Using Trastuzumab–pertuzumab and T-DM1 in HER2-positive Early Breast Cancer: The PHERGain-2 Study." Annals of Oncology, vol. 37, no. 6, 2026, p. 837, https://doi.org/10.1016/j.annonc.2026.01.013.